-
ARCA Cy3 EGFP mRNA (5-moUTP) Workflow
2026-09-15
Build a two-channel assay that distinguishes mRNA uptake from productive translation in mammalian cells. ARCA capping, 5-methoxyuridine modification, and covalent Cy3 labeling make this reagent useful for delivery screening, intracellular trafficking, and EGFP reporter gene expression analysis.
-
(R,S)-Anatabine: A Model-Selection Guide
2026-09-15
Discover how (R,S)-Anatabine connects amyloid precursor protein processing, BACE-1 regulation, and NF-κB signaling in Alzheimer’s research. This guide emphasizes assay selection, orthogonal validation, and lessons from human tissue models.
-
LEE011 Succinate: pH-Aware Assay Design
2026-09-14
Learn how LEE011 succinate can support reproducible CDK inhibitor studies when pH, dissolution, cell-cycle endpoints, and translational context are considered together. This practical guide interprets the key pH-shift findings and converts them into better cancer research workflows.
-
CKI 7 dihydrochloride: Assay Logic for CK1
2026-09-14
Explore how CKI 7 dihydrochloride can clarify Casein kinase 1 biology without being mistaken for a direct MAPK10 probe. This evidence-led guide connects inhibitor controls, Wnt and circadian assays, apoptosis readouts, and NSCLC metastasis research.
-
Dual-Action Inhibitors and p38α Dephosphorylation
2026-09-13
This preprint shows that selected kinase inhibitors can both inhibit p38α MAP kinase activity and accelerate WIP1-mediated dephosphorylation of its activation-loop phosphothreonine. Biochemical and X-ray structural analyses link this effect to an inhibitor-stabilized activation-loop conformation that exposes the phosphatase substrate, suggesting a route to kinase inhibitors with an added signal-termination mechanism.
-
Gramine, the CUL3–MTDH Axis, and TNBC Ferroptosis
2026-09-12
The reference study identifies gramine as an inhibitor of triple-negative breast cancer that acts through a CUL3–MTDH regulatory axis rather than through a nonspecific cytotoxic mechanism alone. By combining target-engagement assays, ferroptosis rescue experiments, genetic knockdown, and xenograft models, the authors connect CUL3-dependent ubiquitination of MTDH with suppression of ferroptosis defenses.
-
Phalloidin B7678: F-Actin Workflow Guide
2026-09-12
Phalloidin (SKU B7678) is a high-affinity F-actin probe for endpoint cytoskeleton visualization in fixed or permeabilized cells, tissue sections, and cell-free assays. It is not appropriate for live-cell imaging or experiments requiring reversible, unperturbed actin remodeling because it stabilizes actin filaments and prevents depolymerization.
-
TET2 Metabolite Binding: Protocol, Findings, and Limits
2026-09-11
Zhang, Cheng, and Ye present an integrated workflow that combines tag-free human TET2 catalytic-domain biochemistry, flow cytometry, and saturation transfer difference NMR to distinguish metabolite binding from functional regulation. The protocol validates known TET2 activators and inhibitors and identifies glyoxylate as a direct-binding candidate, offering a practical framework for connecting metabolism with epigenetic enzyme control.
-
Pregnenolone Carbonitrile: PXR Research Guide
2026-09-11
Pregnenolone Carbonitrile, also called Pregnenolone-16α-carbonitrile, is a rodent PXR agonist used to study xenobiotic metabolism, CYP3A induction, and liver fibrosis pathways. Product specifications and recent PXR research support its use as a mechanistic tool, while species specificity and limited translational evidence define its boundaries.
-
Perphenazine: D2 Antagonist Research Workflows
2026-09-10
Perphenazine supports two complementary research paths: receptor-informed neuropharmacology assays and host-directed antibacterial studies centered on macrophage ROS, autophagy, and lysosomal activity. This workflow guide connects validated cell-death and opioid-tolerance models with practical controls, formulation guidance, and troubleshooting strategies.
-
DAMGO: Reproducible µ-Opioid Assay Design
2026-09-10
This scenario-based guide shows how DAMGO (SKU B6621) can strengthen µ-opioid receptor signaling research while preventing common misinterpretations in viability, receptor activation, and pain-model assays. It links product specifications with published mechanistic evidence to support practical, reproducible experimental decisions.
-
Methylprednisolone: From Inflammation to Bone Models
2026-09-09
Methylprednisolone is more than an anti-inflammatory reagent: it can create a controlled perturbation for connecting glucocorticoid signaling with osteoclast activity and bone architecture. This article explains how to design and interpret a multiscale assay strategy based on a methylprednisolone-induced osteonecrosis model.
-
Anlotinib: From Angiogenesis Assays to Translation
2026-09-09
An evidence-led perspective on how Anlotinib hydrochloride connects VEGFR2, PDGFRβ, FGFR1, and ERK biology with reproducible angiogenesis assays and translational cancer research. The article separates validated findings from workflow recommendations and interprets a published desmoplastic small round cell tumor case without overstating what a single case can prove.
-
Omeprazole (A2845): Practical Research Guide
2026-09-08
Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research and related antiulcer workflows. This guide covers solvent handling, assay setup, quality control, and interpretation limits; the material is for scientific research only and should not be used for diagnosis, treatment, or clinical decision-making.
-
Candida krusei Phase-Specific Apoptosis in BMECs
2026-09-08
Miao and colleagues show that the yeast and hypha phases of Candida krusei trigger bovine mammary epithelial-cell apoptosis through different dominant routes: mitochondrial signaling for yeast cells and death ligand/receptor signaling for hyphae. The study also identifies TLR2/ERK and JNK/ERK signaling as shared regulatory axes, providing a framework for phase-aware mastitis and MAPK signaling pathway research.